author-photo

Lori Steelman

Agios Pharmaceuticals

26

Papers

339

Citations

Citation Trend

Filter By

Papers (19) Sort By

Journal Conference Others

Vorasidenib, a dual inhibitor of mutant IDH1/2, in recurrent or progressive glioma; Results of a first-in-human Phase I trial.

2021 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (5)
NIMG-33. VOLUMETRIC TUMOR MEASUREMENTS ARE SUPERIOR TO 2D BIDIRECTIONAL MEASUREMENTS IN THE EVALUATION OF IDH INHIBITION IN DIFFUSE GLIOMAS: EVIDENCE FROM A PROSPECTIVE PHASE I TRIAL OF IVOSIDENIB

2021 Neuro-oncology
Show All
- Source
- Cite
- Save
Citations (0)
Volumetric measurements are preferred in the evaluation of mutant IDH inhibition in non-enhancing diffuse gliomas: Evidence from a phase I trial of Ivosidenib.

2021 Neuro-oncology
Show All
- Source
- Cite
- Save
Citations (0)
Abstract 2046: Inhibiting IDH mutations in low-grade glioma alters cellular function and the immune environment

2020 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Ivosidenib in Isocitrate Dehydrogenase 1-Mutated Advanced Glioma.

2020 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (45)
Vorasidenib (VOR; AG-881), an inhibitor of mutant IDH1 and IDH2, in patients (pts) with recurrent/progressive glioma: Updated results from the phase I non-enhancing glioma population.

2020 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (2)
INDIGO: A global, randomized, double-blind, phase III study of vorasidenib (VOR; AG-881) vs placebo in patients (pts) with residual or recurrent grade II glioma with an isocitrate dehydrogenase 1/2 (IDH1/2) mutation.

2020 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (3)
Ivosidenib, an IDH1 inhibitor, in a patient with recurrent, IDH1-mutant glioblastoma: a case report from a Phase I study

2020 CNS oncology
Show All
- Source
- Cite
- Save
Citations (8)
ACTR-66. A PHASE 1, OPEN-LABEL, PERIOPERATIVE STUDY OF IVOSIDENIB (AG-120) AND VORASIDENIB (AG-881) IN RECURRENT IDH1 MUTANT, LOW-GRADE GLIOMA: UPDATED RESULTS

2019 Neuro-oncology
Show All
- Source
- Cite
- Save
Citations (7)
PL3.1 A phase 1, open-label, perioperative study of ivosidenib (AG-120) and vorasidenib (AG-881) in recurrent, IDH1-mutant, low-grade glioma: results from cohort 1

2019 Neuro-oncology
Show All
- Source
- Cite
- Save
Citations (2)